In other non-CRC solid tumors subgroup, KN026 plus KN046 also had a relatively higher ORR than that reported in previous studies.35,36 The results highlight the efficacy of HER2-targeted therapies as an effective targeted treatment options for patients with HER2-positive solid tumors. Here, ERBB2 is linked to colorectal carcinoma.